China NMPA Drug Inspection - Jiangxi Heshuo Pharmaceutical Co., Ltd. - Salt-based Psoralea corylifolia

The Guizhou Provincial Drug Administration published its fourth Drug Quality Announcement of 2020 on December 29, 2020, detailing the results of provincial drug sampling inspections. Conducted under the framework of the Drug Administration Law of the People's Republic of China and the Administrative Measures for Drug Quality Sampling Inspection, the oversight initiative identified four batches of non-compliant traditional Chinese medicine products from three specific manufacturers. Bozhou Zhongqiang Traditional Chinese Medicine Pieces Co., Ltd. was cited for Gentian Root that failed moisture standards. Kunming Jingtian Pharmaceutical Co., Ltd. had two products cited: Drynaria, which failed property and identification tests, and Epimedium, which exceeded limits for total ash content. Finally, Jiangxi Heshuo Pharmaceutical Co., Ltd. produced salt-processed Psoralea that failed content determination requirements. All identified violations were measured against the standards set in the 2015 edition of the Chinese Pharmacopoeia. In response to these findings, the Guizhou Provincial Drug Administration has mandated that local regulatory departments initiate legal investigations and prosecutions against the responsible parties. The involved companies are required to implement immediate corrective actions, rectify illegal activities, and strengthen their internal risk prevention and control mechanisms to ensure the future safety and quality of public medications.